tetano
Editor, Senior Moderator
Nature
. 2021 Jun 14.
doi: 10.1038/s41586-021-03696-9. Online ahead of print.
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
Zijun Wang[SUP] #[/SUP][SUP] 1 [/SUP], Frauke Muecksch[SUP] #[/SUP][SUP] 2 [/SUP], Dennis Schaefer-Babajew[SUP] #[/SUP][SUP] 1 [/SUP], Shlomo Finkin[SUP] #[/SUP][SUP] 1 [/SUP], Charlotte Viant[SUP] #[/SUP][SUP] 1 [/SUP], Christian Gaebler[SUP] #[/SUP][SUP] 1 [/SUP], Hans- Heinrich Hoffmann[SUP] 3 [/SUP], Christopher O Barnes[SUP] 4 [/SUP], Melissa Cipolla[SUP] 1 [/SUP], Victor Ramos[SUP] 1 [/SUP], Thiago Y Oliveira[SUP] 1 [/SUP], Alice Cho[SUP] 1 [/SUP], Fabian Schmidt[SUP] 2 [/SUP], Justin da Silva[SUP] 2 [/SUP], Eva Bednarski[SUP] 2 [/SUP], Lauren Aguado[SUP] 3 [/SUP], Jim Yee[SUP] 5 [/SUP], Mridushi Daga[SUP] 1 [/SUP], Martina Turroja[SUP] 1 [/SUP], Katrina G Millard[SUP] 1 [/SUP], Mila Jankovic[SUP] 1 [/SUP], Anna Gazumyan[SUP] 1 6 [/SUP], Zhen Zhao[SUP] 5 [/SUP], Charles M Rice[SUP] 3 [/SUP], Paul D Bieniasz[SUP] 7 8 [/SUP], Marina Caskey[SUP] 9 [/SUP], Theodora Hatziioannou[SUP] 10 [/SUP], Michel C Nussenzweig[SUP] 11 12 [/SUP]
Affiliations
Abstract
Over one year after its inception, the coronavirus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) remains difficult to control despite the availability of several excellent vaccines. Progress in controlling the pandemic is slowed by the emergence of variants that appear to be more transmissible and more resistant to antibodies[SUP]1,2[/SUP]. Here we report on a cohort of 63 COVID-19-convalescent individuals assessed at 1.3, 6.2 and 12 months after infection, 41% of whom also received mRNA vaccines[SUP]3,4[/SUP]. In the absence of vaccination antibody reactivity to the receptor binding domain (RBD) of SARS-CoV-2, neutralizing activity and the number of RBD-specific memory B cells remain relatively stable from 6 to 12 months. Vaccination increases all components of the humoral response, and as expected, results in serum neutralizing activities against variants of concern that are comparable to or greater than neutralizing activity against the original Wuhan Hu-1 achieved by vaccination of naive individuals[SUP]2,5-8[/SUP]. The mechanism underlying these broad-based responses involves ongoing antibody somatic mutation, memory B cell clonal turnover, and development of monoclonal antibodies that are exceptionally resistant to SARS-CoV-2 RBD mutations, including those found in variants of concern[SUP]4,9[/SUP]. In addition, B cell clones expressing broad and potent antibodies are selectively retained in the repertoire over time and expand dramatically after vaccination. The data suggest that immunity in convalescent individuals will be very long lasting and that convalescent individuals who receive available mRNA vaccines will produce antibodies and memory B cells that should be protective against circulating SARS-CoV-2 variants.
. 2021 Jun 14.
doi: 10.1038/s41586-021-03696-9. Online ahead of print.
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
Zijun Wang[SUP] #[/SUP][SUP] 1 [/SUP], Frauke Muecksch[SUP] #[/SUP][SUP] 2 [/SUP], Dennis Schaefer-Babajew[SUP] #[/SUP][SUP] 1 [/SUP], Shlomo Finkin[SUP] #[/SUP][SUP] 1 [/SUP], Charlotte Viant[SUP] #[/SUP][SUP] 1 [/SUP], Christian Gaebler[SUP] #[/SUP][SUP] 1 [/SUP], Hans- Heinrich Hoffmann[SUP] 3 [/SUP], Christopher O Barnes[SUP] 4 [/SUP], Melissa Cipolla[SUP] 1 [/SUP], Victor Ramos[SUP] 1 [/SUP], Thiago Y Oliveira[SUP] 1 [/SUP], Alice Cho[SUP] 1 [/SUP], Fabian Schmidt[SUP] 2 [/SUP], Justin da Silva[SUP] 2 [/SUP], Eva Bednarski[SUP] 2 [/SUP], Lauren Aguado[SUP] 3 [/SUP], Jim Yee[SUP] 5 [/SUP], Mridushi Daga[SUP] 1 [/SUP], Martina Turroja[SUP] 1 [/SUP], Katrina G Millard[SUP] 1 [/SUP], Mila Jankovic[SUP] 1 [/SUP], Anna Gazumyan[SUP] 1 6 [/SUP], Zhen Zhao[SUP] 5 [/SUP], Charles M Rice[SUP] 3 [/SUP], Paul D Bieniasz[SUP] 7 8 [/SUP], Marina Caskey[SUP] 9 [/SUP], Theodora Hatziioannou[SUP] 10 [/SUP], Michel C Nussenzweig[SUP] 11 12 [/SUP]
Affiliations
- PMID: 34126625
- DOI: 10.1038/s41586-021-03696-9
Abstract
Over one year after its inception, the coronavirus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) remains difficult to control despite the availability of several excellent vaccines. Progress in controlling the pandemic is slowed by the emergence of variants that appear to be more transmissible and more resistant to antibodies[SUP]1,2[/SUP]. Here we report on a cohort of 63 COVID-19-convalescent individuals assessed at 1.3, 6.2 and 12 months after infection, 41% of whom also received mRNA vaccines[SUP]3,4[/SUP]. In the absence of vaccination antibody reactivity to the receptor binding domain (RBD) of SARS-CoV-2, neutralizing activity and the number of RBD-specific memory B cells remain relatively stable from 6 to 12 months. Vaccination increases all components of the humoral response, and as expected, results in serum neutralizing activities against variants of concern that are comparable to or greater than neutralizing activity against the original Wuhan Hu-1 achieved by vaccination of naive individuals[SUP]2,5-8[/SUP]. The mechanism underlying these broad-based responses involves ongoing antibody somatic mutation, memory B cell clonal turnover, and development of monoclonal antibodies that are exceptionally resistant to SARS-CoV-2 RBD mutations, including those found in variants of concern[SUP]4,9[/SUP]. In addition, B cell clones expressing broad and potent antibodies are selectively retained in the repertoire over time and expand dramatically after vaccination. The data suggest that immunity in convalescent individuals will be very long lasting and that convalescent individuals who receive available mRNA vaccines will produce antibodies and memory B cells that should be protective against circulating SARS-CoV-2 variants.